United States:
Cooley Alert: Agreements Involving Biosimilars Must Be Reported To FTC And DOJ Under New Law
23 October 2018
Cooley LLP
To print this article, all you need is to be registered or login on Mondaq.com.
Biologic drug makers will soon have to alert the Federal Trade
Commission (FTC) and the U.S. Department of Justice (DOJ) of
agreements, including patent litigation settlements, they reach
with biosimilar applicants. The new reporting requirement is part
of the Patient Right to Know Drug Prices Act, which
President Trump signed into law on October 10, 2018. Read the
full Cooley alert
here.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
Healthcare Policy Developments To Watch In 2024
Crowell & Moring LLP
The ever-changing healthcare policy landscape will witness at the federal level regulatory changes driven by the need to transform healthcare delivery, quality and innovation.
The FDA And The Future Of AI Oversight
Manatt, Phelps & Phillips LLP
In January 2024, the U.S. Government Accountability Office (GAO) issued a report highlighting current obstacles to the U.S. Food and Drug Administration's (FDA) timely and effective regulation...